Tempus AI has announced the clinical launch of the ArteraAI Prostate Test (mHSPC), marking the first externally developed digital pathology algorithm to be integrated into the Tempus ecosystem for clinical use. This CLIA-certified and CAP-accredited prognostic test combines artificial intelligence-powered digital pathology with clinical data to help personalize therapy intensity decisions for patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Clinical Takeaway
The integration of AI-powered digital pathology with genomic sequencing data represents a significant advancement in precision medicine for metastatic prostate cancer. This collaboration addresses a critical treatment gap for approximately 25,000 patients newly diagnosed with metastatic prostate cancer annually in the United States, providing clinicians with enhanced risk stratification tools to optimize therapy selection from the start of the treatment journey.
Technology Platform & Mechanism
- Multimodal AI approach: Combines digitized histopathology images with clinical data to assess cancer aggressiveness
- Risk stratification: Produces personalized risk estimates for prostate cancer-specific mortality likelihood
- Integrated workflow: Seamlessly combines with Tempus’ genomic-based next-generation sequencing (NGS) assay results
- Regulatory status: CLIA-certified and CAP-accredited for clinical use
Target Population
The ArteraAI Prostate Test (mHSPC) is specifically designed for patients with metastatic hormone-sensitive prostate cancer. This represents a targeted approach to addressing treatment decisions for newly diagnosed metastatic disease, where therapy intensity personalization can significantly impact patient outcomes.
Clinical Implementation
- Ordering process: Available as an add-on to Tempus’ solid tumor portfolio across all ordering modalities
- Provider access: Available to urologists and oncologists through the integrated Tempus platform
- Workflow integration: Establishes new digital pathology workflow for enhanced risk stratification
- Comprehensive assessment: Combines pathology-based AI results with genomic sequencing data for more complete disease evaluation
Regulatory Recognition
Artera has received FDA Breakthrough Device Designation for its AI-powered software, highlighting the regulatory recognition of this technology’s potential to transform prostate cancer care. The platform has been validated in multiple Phase 3 randomized trials across different cancer types, demonstrating its clinical utility and evidence base.
Key Clinical Implications
✔ Enhanced precision medicine: First digital pathology algorithm in Tempus ecosystem enables more comprehensive patient assessment
✔ Improved risk stratification: AI-powered analysis of histopathology and clinical data provides personalized mortality risk estimates
✔ Treatment optimization: Helps inform therapy intensity decisions from the start of metastatic prostate cancer care
✔ Streamlined workflow: Integrated platform approach combines genomic and pathology-based insights for comprehensive disease evaluation
Bottom Line
The integration of ArteraAI’s digital pathology algorithm into the Tempus ecosystem represents a meaningful advancement in precision oncology for metastatic prostate cancer. By combining AI-powered histopathology analysis with genomic sequencing data, this collaboration provides clinicians with enhanced tools for risk stratification and therapy personalization, potentially improving treatment outcomes for patients with newly diagnosed metastatic disease. The FDA Breakthrough Device Designation and validation in Phase 3 trials underscore the clinical significance of this multimodal AI approach.
Sources:
- Business Wire. (2026). Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use. https://tinyurl.com/57seusd5
- Artera Press Release. U.S. FDA Grants Artera Breakthrough Device Designation for AI-Powered Software Transforming Prostate Cancer Care. https://tinyurl.com/yc8pbc9x
